Keyword: Alnylam Pharmaceuticals
Eight months removed from handing the reins at Sanofi to Paul Hudson, Oliver Brandicourt is taking a board seat at RNAi therapy maker Alnylam.
Jing Marantz, Senior Vice President, Head of Medical Affairs, Alnylam Pharmaceuticals
Rare diseases can be difficult for kids to understand. And that’s why Alnylam Pharmaceuticals created the “PH1 of a Kind” campaign.
6. Alnylam Pharmaceuticals
While biopharma CEOs often catch the limelight for their multimillion-dollar paychecks, it is every diligent worker that forms a company—and some of them also get paid handsomely. Here, we rank the top 10 most generous biopharma companies by median employee pay in 2018.
The path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from NICE. Fortunately for the drugmaker, that decision was reversed.
Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.
“Game-changing” is just one way analysts and regulators described Alnylam's approval for RNAi drug Onpattro. But the biotech still has work to do.
Alnylam’s first drug approval could come any day now, and to get ready, the company is bulking up—in more ways than one.